🇺🇸 FDA
Pipeline program

A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma

CA1190002

Phase 1 other active

Quick answer

A Phase 1 Study of BMS-986453 in Participants with Relapsed and/or Refractory Multiple Myeloma for Relapsed and/or Refractory Multiple Myeloma is a Phase 1 program (other) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Relapsed and/or Refractory Multiple Myeloma
Phase
Phase 1
Modality
other
Status
active

Clinical trials